PT-141 Dosage Guide: Bremelanotide Dosing, Timing & Protocol (2026)

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist derived from Melanotan II, developed through a series of structural modifications to optimize its pharmacological profile for sexual health research. Unlike sildenafil (PDE5 inhibitors) which act peripherally via vascular smooth muscle, PT-141 acts centrally — it crosses the blood-brain barrier and activates melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors in the hypothalamus, regions associated with sexual arousal pathways. This central mechanism produces a distinctly different research profile: it can stimulate sexual desire (libido) in addition to arousal, making it one of the most studied peptides in both male and female sexual dysfunction research. PT-141 was approved by the FDA as Vyleesi (bremelanotide injection) for hypoactive sexual desire disorder (HSDD) in premenopausal women in 2019, giving it a defined clinical dosing reference point. For research purposes, understanding its unique dosing window, frequency limits, and side effect profile is essential.

Standard PT-141 Dosage Protocols

PT-141's dosing is structured around event-based rather than daily administration. The FDA-approved clinical dose of Vyleesi (bremelanotide) is 1.75 mg SubQ 45 minutes before sexual activity, providing a regulatory anchor for research dose calibration:

Doses above 2 mg are not used in standard research protocols and are associated with a significant increase in adverse events without corresponding benefit. The 0.5 mg starting dose is strongly recommended for initial exposure to characterize individual sensitivity before advancing to higher doses.

Dosing Frequency

PT-141 is not designed for daily use. Its frequency limits are among the most important distinguishing features of its research protocol:

• FDA-approved maximum: Once per 24 hours, no more than one dose per use occasion, not for daily use (per Vyleesi prescribing information).
• Common research framework: 2–3 uses per week maximum in sexually active adult research models. Most protocols allow 1–2 uses per week to minimize cumulative blood pressure effects.
• Not suitable for daily dosing: Unlike GH secretagogues or healing peptides, PT-141 has no rationale for daily dosing. Its mechanism is situational and its side effects (particularly blood pressure elevation and nausea) accumulate with frequent use.
• Washout between uses: A minimum of 24 hours between doses is mandatory. Many researchers build in 48–72 hours between uses to allow full recovery of blood pressure parameters and reduce nausea sensitization.

Cycle Structure

PT-141's event-based dosing makes traditional "cycles" less applicable than for continuously-dosed peptides. Research protocols typically define PT-141 use in terms of total number of administrations over a study period:

Acute/event-based research

Most PT-141 research is structured as acute, event-based administration — subjects receive PT-141 or placebo before specific research sessions. No extended "loading" or "maintenance" phase is used.

Longitudinal research design

In studies examining chronic HSDD or sexual dysfunction, PT-141 may be used 2–4 times per week over an 8–12 week study window. The primary endpoint in these designs is typically frequency of satisfying sexual events or scores on validated sexual function scales (e.g., FSFI, FSDS-R).

Tolerance and desensitization

Melanocortin receptors can undergo downregulation with repeated stimulation. Research protocols monitoring for tolerance typically include periodic dose-free periods (e.g., 1 week off per month) to assess for receptor desensitization. The clinical Vyleesi trial data did not demonstrate significant tolerance development over 6 months at once-per-event dosing, but more frequent use is less characterized.

Reconstitution Guide

PT-141 is supplied as a lyophilized powder, typically in 10 mg vials. Bacteriostatic water (BAC water) is the standard reconstitution solvent.

Step-by-step reconstitution

1. Allow the vial to reach room temperature before opening.
2. Clean the rubber stopper with a 70% isopropyl alcohol swab and allow to dry.
3. Draw the desired volume of BAC water into a syringe (see concentrations below).
4. Insert the needle at an angle and allow the water to run down the inside wall of the vial, not directly onto the powder.
5. Gently swirl (do not shake) until completely dissolved. The solution will be clear and colorless.
6. Label with reconstitution date and store at 2–8°C.

Resulting concentrations (10 mg vial)

• 2 mL BAC water → 5,000 mcg/mL (1 mg dose = 0.2 mL)
• 5 mL BAC water → 2,000 mcg/mL (1 mg dose = 0.5 mL)
• 10 mL BAC water → 1,000 mcg/mL (1 mg dose = 1.0 mL)

The 2 mL dilution (5,000 mcg/mL) keeps injection volumes small — a 1.75 mg dose is only 0.35 mL, easily delivered in a 0.5 mL insulin syringe. Reconstituted PT-141 in BAC water is stable at 2–8°C for 28–30 days.

Injection Guide

SubQ technique

PT-141 is administered subcutaneously in both research and clinical (Vyleesi) settings. The FDA-approved Vyleesi auto-injector delivers into the abdomen or thigh.

For research use:

• Use a 29–31 gauge, 0.5-inch insulin syringe
• Standard injection sites: lower abdomen (1–2 inches from navel) or outer thigh
• Pinch skin, insert at 45–90°, inject slowly, withdraw and apply light pressure
• Rotate sites between uses

Timing — the most critical dosing variable

PT-141's onset of action is slower than peripheral vasodilators. Key timing data:

• Onset: 45–60 minutes after SubQ injection in most subjects
• Peak effect: 60–120 minutes post-injection
• Duration: Effects typically last 6–12 hours, with some subjects reporting extended duration up to 24 hours
• Recommended pre-administration window: 45–90 minutes before the planned research session

The long duration of action means nausea and blood pressure effects also persist for 6–12 hours post-injection. Research protocols should account for this in subject scheduling and monitoring windows.

Food and alcohol interactions

Food does not meaningfully alter PT-141's pharmacokinetics for SubQ delivery. Alcohol co-administration is generally avoided in research protocols due to combined blood pressure effects and the potential to mask or confound CNS-mediated arousal endpoints.

Stacking PT-141

PT-141 is typically studied as a standalone compound due to its specific sexual function application. However, some research contexts examine it in combination:

• PT-141 + PDE5 inhibitors (sildenafil/tadalafil): Studied in male erectile dysfunction models where both central (PT-141) and peripheral (PDE5 inhibitor) mechanisms are engaged. Important caution: both compounds lower blood pressure through different mechanisms, and their combination produces additive hypotensive effects. This combination requires careful blood pressure monitoring in research settings.
• PT-141 + Melanotan II: Melanotan II is a related melanocortin agonist with tanning and sexual effects. Combining the two is redundant (both act on MC3R/MC4R) and amplifies side effects. Not a recommended research stack.
• PT-141 + oxytocin: Studied in relationship satisfaction and bonding research. Oxytocin is a distinct neuropeptide with prosocial and arousal-facilitating effects. Research models combining these have been published in the sexual psychology literature.

Side Effects & Safety Considerations

PT-141's side effect profile is well-documented from its FDA clinical trial program. Researchers should be specifically aware of:

• Nausea: The most common adverse event in clinical trials — reported in ~40% of subjects at 1.75 mg. Nausea onset is typically 1–2 hours post-injection and may last 2–4 hours. Starting at 0.5 mg significantly reduces incidence. Anti-nausea medications (e.g., ondansetron) are used in clinical protocols; researchers should have a management plan.
• Blood pressure elevation: A clinically significant concern. PT-141 causes a transient increase in systolic blood pressure (approximately 6 mmHg mean increase) beginning 1–2 hours post-injection and lasting 8–12 hours. A transient compensatory decrease in blood pressure may follow. Contraindicated in clinical settings for subjects with uncontrolled hypertension or high cardiovascular risk. Research protocols should include BP monitoring.
• Facial flushing: Common, transient, mechanism-related (melanocortin receptor activation in skin vasculature). Typically resolves within 1–2 hours.
• Hyperpigmentation: Repeated PT-141 use can produce transient or lasting skin darkening, particularly on the face and in skin folds. This is an on-target effect of MC1R activation in melanocytes. More pronounced at higher doses and with repeated use.
• Headache: Reported in clinical trials; typically mild and self-limiting.
• Yawning: A distinctive and characteristic effect of melanocortin agonists. Yawning is often used as a behavioral proxy for PT-141 activity onset in research protocols.
• Spontaneous erections (male subjects): Dose-dependent and mechanism-driven. This is the desired effect in ED research models but should be documented as an expected event in research consent frameworks.

Frequently Asked Questions